Loading organizations...
EdiGene is a Beijing-based biotechnology company that develops genome editing technologies to accelerate drug discovery and create novel therapeutics for genetic diseases and cancers. The organization leverages proprietary platforms, including ex vivo editing for hematopoietic stem cells and in vivo RNA base editing, to advance gene-editing therapies toward clinical trials. Operating with a global workforce of over 100 professionals, the company has raised approximately $229 million in total funding, including a $67 million Series B in 2020 and a $62 million Series B+ in 2021. This financial backing comes from prominent venture capital firms such as Sequoia Capital China, IDG Capital, 3H Health Investment, and Loyal Valley Capital. The firm also recently initiated a Phase I clinical trial for its ET-01 therapy targeting β-thalassemia. EdiGene was founded in 2015 by scientific founder Wensheng Wei.
EdiGene has raised $164.4M across 5 funding rounds.
EdiGene has raised $164.4M in total across 5 funding rounds.
EdiGene has raised $164.4M in total across 5 funding rounds.
EdiGene's investors include Andy Lin, 3H Health Investment, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, Minchuan Wang, Green Pine Capital Partners, Fei Luo, Fei Chen.
EdiGene has raised $164.4M across 5 funding rounds. Most recently, it raised $61.5M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 21, 2021 | $61.5M Series B | Andy LIN | 3H Health Investment, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures, Sherpa Healthcare Partners | Announced |
| Oct 13, 2020 | $66.9M Series B | Minchuan Wang | Green Pine Capital Partners, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures | Announced |
| Sep 16, 2019 | $11M Series A Plus | IDG Capital, Lilly Asia Ventures | — | Announced |
| Feb 4, 2019 | $10M Series A Plus | FEI LUO | IDG Capital, Lilly Asia Ventures | Announced |
| Aug 8, 2018 | $15M Series A Plus | FEI Chen | Huagai Capital, IDG Capital, WI Harper Group | Announced |
